ZS Pharma, Inc.

Operating margin

—

Net margin

—

Return on equity

−11.1%

Return on assets

−9.3%

Return on capital (ROCE)

−8.7%

Liabilities / assets

16.7%

Debt / equity

0.20×

Book value / share

$4.63

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

6.81safe

Accruals / assets

32.9%high accruals

Piotroski F-Score

3/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 17, 2015
• Other material eventNov 6, 2015
• Entered a material agreement · Other material eventNov 6, 2015
• Other material eventSep 10, 2015
• Results of operationsAug 6, 2015
• Other material eventJul 29, 2015
• Director / officer change · Shareholder voteJun 23, 2015
• Director / officer changeJun 16, 2015

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.